ERBB2 and ductal breast carcinoma in situ: Studies have found that in IDC-DCIS, the proportion of triple-negative molecular types is relatively small, while the proportion of Her-2 positive and HR positive patients is relatively large (Goh et al. 2019; Kole et al. 2019; Guan et al. 2020; Carabias-Meseguer et al. 2013).